The company expects to use the net proceeds to support the additional growth of the company including pursuit of commercial opportunities for Lymphoseek outside the U.S., the continued development of its neurodegenerative imaging portfolio, further evaluation of Manocept platform initiatives, and other general corporate purposes.
If Crede was doing DD and saw that Lymphoseek sales were weak, all they would have to do is wait until the 3rd quarter earnings report. IF LS sales are bad, the stock is going to tank. Crede could get a good deal on stock to hold for the long term.
I just stated two reasons why else and who knows what else could be cooking. Nobody knows nothing regarding sales, except for maybe Crede CG. I wonder why they would bailout poor old NAVB by purchasing over 10mil shares at market value? A head scratcher, wouldn't you say?